The FDA's approval was based on a study of 11,400 people age 12 and older that compared the new low-dose vaccine with Moderna's existing vaccine. It found the new vaccine was safe and was at least as ...

The Centers for Disease Control and Prevention's vaccine advisory committee is set to meet for the first time since Health ...

The meeting, scheduled for June 25-26, will review existing data and vote on RSV and influenza vaccines, along with ...

NEXSPIKE becomes Moderna’s third FDA-approved product CAMBRIDGE, MA / ACCESS Newswire / May 31, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has ...

The mNexspike vaccine is supplied as a single-dose prefilled syringe containing 1 dose of 0.2mL. The single 0.2mL dose should be administered at least 3 months after the last dose of COVID-19 vaccine.

The Food and Drug Administration (FDA) has approved Moderna’s next-generation mRNA COVID-19 vaccine mNexspike ®.

mNexspike becomes Moderna’s third FDA-approved product, joining Spikevax (original COVID-19 vaccine) and mResvia (RSV vaccine). Spikevax is approved/authorized for use by the FDA in individuals ...

June 2, 2025 -- The FDA has approved Moderna's new COVID-19 shot, an mRNA vaccine, with some limits on who can get it.. The vaccine, called mNexspike, is for people who’ve previously received a ...

The new vaccine, mNexspike (mRNA-1283), is a step toward next-generation coronavirus vaccines. It’s made in a way that allows for a lower dose, a fifth of the dose of its current COVID-19 vaccine, Spi ...

Moderna’s mNEXSPIKE (mRNA-1283), a new COVID-19 vaccine, received FDA approval based on Phase III trial data showing higher relative vaccine efficacy than Spikevax. The vaccine will be available for ...